<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784848</url>
  </required_header>
  <id_info>
    <org_study_id>IEP2013_HAS</org_study_id>
    <nct_id>NCT01784848</nct_id>
  </id_info>
  <brief_title>GAstric Bypass to Treat obEse Patients With steAdy hYpertension</brief_title>
  <acronym>GATEWAY</acronym>
  <official_title>Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3, unicentric, randomized clinical trial, with allocation concealment and
      intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y
      Gastroplasty to decrease the prescription of antihypertensive drugs maintaining normal levels
      of blood pressure, decrease systemic arterial blood pressure and other risk factors for
      cardiovascular events compared to clinical treatments of patients with arterial hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization:

      The randomization list is electronically generated through specific software. A block
      randomization is conducted with varying block sizes at the rate of 1:1. Confidentiality of
      the randomization list is ensured by the central automated randomization system, through the
      Internet, available 24 hours a day (ACT Clinic - Sistema de Estudos Clínicos do IEP HCor).

      Blinding Scheme:

      Because the study involves a surgical procedure, investigators and patients cannot be blind
      for treatment allocated to patients.

      Roux-en-Y Gastroplasty Patients allocated to surgical treatment will be admitted to the
      hospital to be subjected to a Roux-en-Y gastric bypass with a biliopancreatic loop of 100cm
      and a alimentary limb of 150cm.

      Antihypertensive Treatment:

      The treatment of hypertension will be standardized for all study patients. Prescribed drugs
      will include preferably a renin-angiotensin blocking system drug and a calcium channels
      blocker, except if these are contraindicated or the patient has achieved good blood pressure
      control using other drugs prior to study recruitment. Other drugs can be added at discretion
      of the attending investigator to achieve a target blood pressure of 130 x 80 mmHg. Patients
      are treated individually for the other associated comorbidities. Obesity treatment in the
      control group includes dietary advice, motivation for the practice of physical activities,
      and drug treatments for diabetes and dyslipidemias if applicable.

      Laboratory tests and other exams:

      All patients will be subjected to the following measurements throughout the study:

        -  Outpatient Blood Pressure Monitoring (ABPM)

        -  Blood pressure measurements taken in doctors' offices:

        -  Central pressure and associated measurements (SphygmoCor®)

        -  Polysomnography

        -  Anthropometry

        -  Nutritional survey

        -  Laboratory tests

        -  Echocardiogram

        -  Electrocardiogram

        -  Abdominal ultrasound

        -  Upper gastrointestinal endoscopy with H.pylori testing
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (&lt;140x90 mmHg), in 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Roux-en-Y Gastroplasty to Decrease the Number of Antihypertensive Drugs.</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (&lt;140x90 mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Blood Pressure Levels</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Change on systemic blood pressure assessed by ambulatory blood pressure monitoring (ABPM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Central Blood Pressure Augmentation Index and Pulse Wave Velocity</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Change on central blood pressure augmentation index and pulse wave velocity as measured by SphygmoCor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Systolic Blood Pressure</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline in systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Diastolic Blood Pressure</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline in diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Weight Loss</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on BMI</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Waist Circumference</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Fasting Plasm Glucose Level, HbA1c and Insulin Resistance</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Change from baseline on fasting plasm glucose level, HbA1c and insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on LDL-cholesterol Level</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on LDL-cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on HDL-cholesterol Level</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on HDL-cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Triglycerides Levels</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on triglycerides levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Uric Acid Levels</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on uric acid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline on Ultra-sensitive CRP Levels</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline on ultra-sensitive CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline of Cardiovascular Risk</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Absolute change from baseline of cardiovascular risk calculated by Framingham Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Heart Anatomy</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Change on heart anatomy as evaluated by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Sleep Quality</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Change on sleep quality as evaluated by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>At any time during the study period</time_frame>
    <description>Describe the main adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Systemic Hypertension</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Laparoscopic Roux-en-Y gastric bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimized clinical treatment including medical management of hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Roux-en-Y gastric bypass (LRYGB)</intervention_name>
    <description>Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery</description>
    <arm_group_label>Laparoscopic Roux-en-Y gastric bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical treatment</intervention_name>
    <description>Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
    <arm_group_label>Clinical treatment</arm_group_label>
    <arm_group_label>Laparoscopic Roux-en-Y gastric bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged between 18 and 65 years old.

          -  hypertension diagnosis defined as in use of at least 2 high blood pressure medication
             at full doses.

          -  body mass index between 30,0 and 39,9 kg/m2.

        Exclusion Criteria:

          -  hypertension ≥ 180/120 mmHg;

          -  cerebrovascular diseases in the last 6 months.

          -  Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last 6
             months.

          -  Baseline psychiatric disorders: schizophrenia, bipolar disorder, severe depression,
             psychosis.

          -  Renal diseases: diabetic nephropathy, creatinine clearance &lt; 30 ml/min.

          -  Patients with secondary hypertension except due to the sleep apnea.

          -  Advanced peripheral arterial disease

          -  atrophic gastritis

          -  Diabetes mellitus type 1 and type 2 with HbA1 c &gt;7,0%

          -  alcoholism or use of illicit drugs

          -  smokers

          -  previous laparotomy

          -  severe hepatic disorders

          -  Pregnancy or women not using effective contraceptive methods.

          -  Recent neoplasm (&lt; 5 years)

          -  Immunosuppressant drugs

          -  Unable to understanding and follow the study protocol orientations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos A Schiavon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coração</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04004-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração - Hospital das Clínicas de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04004-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Coração - Research Institute</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04005-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, Frayha JC, Santos RN, Damiani LP, Noujaim PM, Halpern H, Monteiro FLJ, Cohen RV, Uchoa CH, de Souza MG, Amodeo C, Bortolotto L, Ikeoka D, Drager LF, Cavalcanti AB, Berwanger O. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018 Mar 13;137(11):1132-1142. doi: 10.1161/CIRCULATIONAHA.117.032130. Epub 2017 Nov 13. Erratum in: Circulation. 2019 Oct;140(14):e718.</citation>
    <PMID>29133606</PMID>
  </results_reference>
  <results_reference>
    <citation>Schiavon CA, Ikeoka D, Santucci EV, Santos RN, Damiani LP, Bueno PT, Oliveira JD, Torreglosa CR, Bersch-Ferreira AC, Miranda TA, Barros S, Halpern H, Monteiro FLJ, Cohen RV, Noujaim PM, de Souza MG, Amodeo C, Bortolotto LA, Berwanger O, Cavalcanti AB, Drager LF. Effects of Bariatric Surgery Versus Medical Therapy on the 24-Hour Ambulatory Blood Pressure and the Prevalence of Resistant Hypertension. Hypertension. 2019 Mar;73(3):571-577. doi: 10.1161/HYPERTENSIONAHA.118.12290.</citation>
    <PMID>30661477</PMID>
  </results_reference>
  <results_reference>
    <citation>Schiavon CA, Santos RN, Santucci EV, Noujaim PM, Cavalcanti AB, Drager LF. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial. Surg Obes Relat Dis. 2019 Feb;15(2):211-217. doi: 10.1016/j.soard.2018.11.022. Epub 2018 Nov 27.</citation>
    <PMID>30679036</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high blood pressure</keyword>
  <keyword>hypertension</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>Laparoscopic Roux-en-Y gastric bypass (LRYGB)</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT01784848/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT01784848/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laparoscopic Roux-en-Y Gastric Bypass</title>
          <description>Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
Laparoscopic Roux-en-Y gastric bypass (LRYGB): Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
        </group>
        <group group_id="P2">
          <title>Clinical Treatment</title>
          <description>Optimized clinical treatment including medical management of hypertension.
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laparoscopic Roux-en-Y Gastric Bypass</title>
          <description>Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
Laparoscopic Roux-en-Y gastric bypass (LRYGB): Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
        </group>
        <group group_id="B2">
          <title>Clinical Treatment</title>
          <description>Optimized clinical treatment including medical management of hypertension.
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="9.2"/>
                    <measurement group_id="B2" value="44.6" spread="9.2"/>
                    <measurement group_id="B3" value="43.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-hypertensive medications</title>
          <units>Anti-hypertensive medications</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B2" value="3" lower_limit="3" upper_limit="3"/>
                    <measurement group_id="B3" value="3" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg</title>
        <description>Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (&lt;140x90 mmHg), in 12 months.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laparoscopic Roux-en-Y Gastric Bypass</title>
            <description>Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
Laparoscopic Roux-en-Y gastric bypass (LRYGB): Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
          </group>
          <group group_id="O2">
            <title>Clinical Treatment</title>
            <description>Optimized clinical treatment including medical management of hypertension.
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg</title>
          <description>Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (&lt;140x90 mmHg), in 12 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Roux-en-Y Gastroplasty to Decrease the Number of Antihypertensive Drugs.</title>
        <description>Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (&lt;140x90 mmHg).</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Blood Pressure Levels</title>
        <description>Change on systemic blood pressure assessed by ambulatory blood pressure monitoring (ABPM).</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Central Blood Pressure Augmentation Index and Pulse Wave Velocity</title>
        <description>Change on central blood pressure augmentation index and pulse wave velocity as measured by SphygmoCor device</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Systolic Blood Pressure</title>
        <description>Absolute change from baseline in systolic blood pressure</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Diastolic Blood Pressure</title>
        <description>Absolute change from baseline in diastolic blood pressure</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Weight Loss</title>
        <description>Absolute change from baseline on weight loss</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on BMI</title>
        <description>Absolute change from baseline on BMI</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Waist Circumference</title>
        <description>Absolute change from baseline on waist circumference</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Fasting Plasm Glucose Level, HbA1c and Insulin Resistance</title>
        <description>Change from baseline on fasting plasm glucose level, HbA1c and insulin resistance</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on LDL-cholesterol Level</title>
        <description>Absolute change from baseline on LDL-cholesterol level</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on HDL-cholesterol Level</title>
        <description>Absolute change from baseline on HDL-cholesterol level</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Triglycerides Levels</title>
        <description>Absolute change from baseline on triglycerides levels</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Uric Acid Levels</title>
        <description>Absolute change from baseline on uric acid levels</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline on Ultra-sensitive CRP Levels</title>
        <description>Absolute change from baseline on ultra-sensitive CRP levels</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline of Cardiovascular Risk</title>
        <description>Absolute change from baseline of cardiovascular risk calculated by Framingham Score</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change on Heart Anatomy</title>
        <description>Change on heart anatomy as evaluated by echocardiogram</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change on Sleep Quality</title>
        <description>Change on sleep quality as evaluated by polysomnography</description>
        <time_frame>12, 24, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Describe the main adverse events</description>
        <time_frame>At any time during the study period</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Laparoscopic Roux-en-Y Gastric Bypass</title>
          <description>Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
Laparoscopic Roux-en-Y gastric bypass (LRYGB): Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
        </group>
        <group group_id="E2">
          <title>Clinical Treatment</title>
          <description>Optimized clinical treatment including medical management of hypertension.
Clinical treatment: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rehospitalization</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Carlos Schiavon</name_or_title>
      <organization>HCor</organization>
      <phone>1130536611 ext 8201</phone>
      <email>schiavon.ca@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

